Filing Details

Accession Number:
0001104659-23-107367
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-06 08:37:31
Reporting Period:
2023-10-04
Accepted Time:
2023-10-06 08:37:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1875558 Nuvectis Pharma Inc. NVCT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1251213 Ron Bentsur C/O Nuvectis Pharma, Inc.
1 Bridge Plaza, Suite 275
Fort Lee NJ 07024
Chairman & Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-10-04 1,820 $10.95 3,234,364 No 4 P Direct
Common Stock Acquisiton 2023-10-05 1,400 $11.09 3,235,764 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.76 to $11.236. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
  2. Includes 426,759 shares of restricted stock.
  3. Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.7875 to $11.32. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.